BOSTON/NEW YORK (Reuters) - Billionaire investor William Ackman on Monday mounted a vigorous defense of Valeant Pharmaceuticals , ruling out any sale of the drug company's "crown jewel" assets but saying price cuts and even a new name may be in its future.
Read more
No comments:
Post a Comment